Related by context. All words. (Click for frequent words.) 63 kidney urologic 63 randomized controlled multicenter 62 BrachySil TM 62 multicenter Phase II 62 EchoCRT 61 Rheos System 61 Litx 61 trial evaluating PRX# 61 adipose derived stem cell 61 Phase Ib IIa 61 Phase IIb III 61 ASPIRE HIGHER 60 acyclovir Lauriad R 60 randomized discontinuation 60 phase IIb clinical 60 Bayer HealthCare Onyx Pharmaceuticals 60 biliary tract cancer 60 Aplidin 60 Phase #b/#a clinical 59 rALLy clinical trial 59 multicenter randomized placebo controlled 59 ospemifene 59 BioNumerik 59 YONDELIS R 59 BRIM2 59 NP2 Enkephalin 59 AE# vaccine 59 genomic profiling 59 HepaMate ™ 59 ADVANCE PD 59 imetelstat GRN#L 59 adrenergic regulation 59 humanised antibody 59 Phase Ib II 59 Curaxin CBLC# 59 reslizumab 59 cGMP manufacture 59 LHRH receptor positive 59 double blinded randomized 58 GCP compliant 58 Erimos 58 randomized Phase IIb 58 multicenter randomized clinical 58 YONDELIS 58 phase Ib clinical 58 DEEP AF 58 AFRS TM 58 Cx# [002] 58 relapsing remitting MS RRMS 58 CA9 SCAN 58 vivo validation 58 therapeutic monoclonal antibody 58 riociguat 58 dose escalation clinical 58 metastatic neuroendocrine tumors 58 registrational Phase 58 PhG alpha 1 58 TASKi3 58 p# biomarker 58 telomerase activator 58 flavopiridol 58 BrainGate TM 58 INS# [001] 58 CURE AF 58 Curaxin 58 oral antiplatelet agent 58 Prodarsan R 58 trastuzumab DM1 T DM1 58 OncoVex 58 bioartificial liver 58 designated HVTN 58 myoblast 58 IMA# 58 Phase Ib IIa clinical 57 placental derived 57 NO# [002] 57 ONCONASE R 57 mertansine 57 GORE TAG Device 57 cilengitide 57 thymosin beta 4 57 blinded randomized placebo controlled 57 Monoclonal antibody 57 pivotal bioequivalence 57 randomized controlled Phase 57 BRIM3 57 VITAL Trial 57 acadesine 57 placebo controlled Phase III 57 vivo preclinical 57 Trofex 57 Phase IIIb clinical 57 Phase III VISTA 57 Hepatocellular Carcinoma HCC 57 multicenter Phase III 57 fosbretabulin 57 NeuroFlo 57 PDE# inhibitors 57 INxin 57 Poly ICLC 57 phase IIa clinical 57 Neo Bladder Augment 57 REGEN trial 57 MultiGEN 57 MIST II 57 BrachySil ™ 57 anticoagulant reversing agent 57 BioControl 57 TransMID 57 undergoing hematopoietic stem 57 OMP #R# 57 adult mesenchymal stem 57 recurrent glioma 57 blinded randomized 57 allogeneic cell 57 Rosetta Genomics microRNA 57 Celution TM System 57 Proellex TM 57 IMPACT DCM clinical 57 StemEx R 56 PFO migraine 56 pain palliation 56 PrevOnco 56 PrevOnco ™ 56 OHR/AVR# 56 Affimed Therapeutics AG 56 Exherin TM 56 GRNVAC1 56 Adult Stem Cell Therapy 56 IIa clinical trials 56 CHAMPION PCI 56 SNT MC# 56 BR.# 56 ReN# 56 Factor VIIa 56 Phase III multicenter 56 confirmatory clinical 56 afamelanotide 56 Phase IIIb 56 hESC derived RPE cells 56 SPECT CT imaging 56 engineered bladders 56 delipidation 56 tramiprosate Alzhemed TM 56 StemEx 56 stem cell engraftment 56 recombinant PSMA vaccine 56 rotary VAD 56 HuCNS SC ® 56 CardioFit 56 including eniluracil ADH 56 Plasmin 56 intravitreal insert 56 relapsed leukemia 56 SoftScan ® 56 immunotherapeutic vaccine 56 pharmacogenomic translational research 56 diagnostic biomarker 56 AEG# 56 UPLYSO 56 personalized dendritic 56 trodusquemine 56 OncoGel 56 Tectin TM 56 Daclizumab 56 MKC# MKC# PP 56 placebo controlled Phase 56 TG MV 56 NuroPro PD 56 MAGE A3 ASCI 56 ZFP Therapeutics 56 immunogenetics 56 mesenchymal stem cell 56 Bryostatin 56 improve impulse conduction 56 thetreatment 56 Kahalalide F 56 IIa trials 56 Corus CAD 56 PET tracers 56 PolyHeme ® 56 multicenter phase 56 Phase Ib clinical 56 Feasibility Trial 56 papillary renal cell carcinoma 56 miglustat 56 cartilage regeneration 56 Virulizin ® 56 Vimpat ® lacosamide 56 multicenter randomized controlled 56 ALN VSP Phase 56 AA amyloidosis 55 CCR9 antagonist 55 Phase #b/#a 55 forodesine 55 Squalamine 55 dexanabinol 55 polycythemia vera PV 55 ZACTIMA 55 LEAPS TM 55 Phase III Pivotal 55 Phase IIIb study 55 phase III ACCLAIM 55 HCD# [002] 55 placebo controlled clinical 55 oral Janus kinase 55 CholeraGarde R 55 cortical stimulation 55 Aplidin R 55 CATIE AD 55 ExCell study 55 JCSG 55 multicenter dose escalation 55 Phase 1b clinical trials 55 ATIR TM 55 Pagoclone 55 multicenter clinical 55 Phase 2b kidney transplant 55 Phase IIb kidney transplant 55 pediatric rehydration 55 Proxinium TM 55 CBLC# 55 Ceflatonin 55 HepDirect prodrug 55 antibody MAb 55 receptor tyrosine kinase inhibitor 55 novel therapeutic antibodies 55 treatment naive genotype 55 #I TM# 55 LUMINATE 55 European Sepsis Trial 55 SCENESSE ® 55 Nuron Biotech 55 pacemaker manufacturer Intrapace 55 PI3K/Akt pathway inhibitor 55 transgenically produced product 55 NPC 1C 55 Glypromate 55 EP #R 55 Oxiplex 55 ToGA 55 hyaluronidase enzyme 55 Novo TTF 55 Phase IIb clinical trials 55 GRNOPC1 contains 55 bardoxolone 55 virology immunology 55 uricase 55 ganaxolone 55 GRN# 55 GLP toxicology 55 CINtec R 55 SUTENT ® 55 blood clot dissolver 55 randomized multicenter trial 55 AFREZZA TM 55 fusion enhancers 55 PD LID 55 phase Ib 55 therapeutically specialized 55 SomatoKine 55 Ataluren 55 AKT inhibitor 55 BCR ABL inhibitor 55 adipose stem 55 targeted radiotherapeutic 55 QLT Plug Delivery 55 multicenter trials 55 treating cancerous tumors 55 PRESEPT study 55 DXL# 54 Bioral Amphotericin B 54 HuCAL antibodies 54 optical biosensors 54 alvespimycin 54 adipose derived regenerative 54 GeoVax vaccine 54 Anti VEGF 54 phase IIa 54 preclinical efficacy 54 double blinded placebo 54 Phase 1a clinical 54 gamma secretase inhibitor 54 thorough QT 54 commercialize deforolimus 54 AERAS-#/Crucell Ad# 54 onco 54 TrialNet 54 HDL Selective Delipidation 54 IAP inhibitor 54 Pimavanserin 54 phase IIb III 54 neuroimmunology 54 LungSign TM 54 prospective randomized multicenter 54 ACTCellerate 54 evaluating Actimmune 54 GVAX ® 54 PRESEPT 54 radiolabeled TM# 54 Solazed 54 IL# PE#QQR 54 Stargardt Macular Dystrophy SMD 54 Phase IIB 54 HQK 54 bortezomib Velcade 54 ReN# stem cell 54 injectable collagenase 54 accumulate preferentially 54 Phase IIA 54 galiximab 54 acyclovir Lauriad ® 54 ESBA# 54 Cell TRC 54 GGF2 54 oral prodrug 54 IIa clinical 54 Mipomersen 54 WRAIR 54 fidaxomicin Phase 3 54 Andara TM OFS 54 IMPACT DCM 54 Vasogen Celacade TM 54 Dacogen decitabine 54 multicenter Phase 54 Rudloe Dickerson Bay 54 Spheramine 54 Lofexidine 54 Vascugel 54 phosphatidylserine PS targeting 54 human IgG1 monoclonal 54 Prof. Gozes 54 Oncotype DX colon cancer 54 NSABP 54 RhuDex 54 catheter occlusion 54 JAK#/JAK# inhibitor CYT# 54 Gleevec resistant 54 taxane derivative 54 intratumoral injection 54 DP VPA 54 antisense inhibitor 54 Systemic Delivery 54 cellular immunotherapy 54 cetrorelix pamoate 54 ENDEAVOR IV 54 sd rxRNA 54 GAMMAGARD 54 PLX cells 54 nonsmall cell lung cancer 54 MelaFind R 54 Lpathomab 54 CCR5 mAb 54 choroidal vasculopathy 54 WallFlex Biliary RX 54 PEARL SC 54 farletuzumab 54 VersaFilm 54 SEPET TM 54 BRAF inhibitors 54 ChronVac C R 54 oral ghrelin agonist 54 OvaRex R 54 DF HCC 54 invasive candidiasis 54 AA Amyloidosis 54 HeartNet 54 CoAxia 54 Aalst Belgium 54 targeted antifolate 54 volociximab 54 Anturol TM 54 Phase III randomized controlled 54 PSMA ADC 54 NanoStat 54 recurrent metastatic ovarian cancer 54 hypoxia activated prodrug 54 potent inducer 54 neurogenic bladder 54 dose escalation Phase 54 bioanalytical laboratories 54 CMV vaccine 54 HepaMate 53 Xcellerated T Cells 53 Dr. Gabriel Lasala 53 BHT DNA 53 autologous adult 53 allogeneic bone marrow 53 juvenile chondrocytes 53 HGS# 53 transplantation HSCT 53 fistulizing Crohn disease 53 metabonomics 53 Traficet EN 53 Endoscopic Ablation System 53 Cloretazine ® 53 GelSite polymer 53 bronchogenic carcinoma 53 Dr. Fehlings 53 JAK inhibitors 53 Valtropin 53 Biocept 53 edifoligide E2F Decoy 53 ENGAGE AF TIMI 53 myoblast therapy 53 R#/MEM # 53 Novolimus 53 lomitapide 53 Sorafenib HCC Assessment 53 Lumbar Interbody Fusion 53 PET CT scanning 53 developed preclinically 53 Zalypsis 53 Oncologic 53 Degarelix 53 triphendiol 53 anticancer therapeutics 53 monocyte derived 53 Myoblast Program 53 tolevamer 53 Voraxaze 53 oral dnaJP1 53 LUVENIQ 53 tiapamil 53 omega interferon 53 EOquin TM 53 diaphragm pacing 53 Elekta Axesse 53 CytoFabTM 53 MT#/MEDI-# 53 randomized Phase III 53 huN# DM1 53 nucleotide analogue 53 BEZ# 53 bioartificial kidney 53 BMAC System 53 TLK# 53 preclinical toxicology 53 antiangiogenic agent 53 CINQUIL 53 cleavable linker 53 Sipuleucel T 53 Cethrin 53 OrCel ® 53 number NCT# ClinicalTrials.gov 53 initiate Phase 1b 53 Neurostep TM 53 BRAF inhibitor 53 humanized therapeutic 53 immunotherapeutic agent 53 OncoVEX 53 Deforolimus 53 vemurafenib 53 LUX Lung 53 potent topoisomerase II 53 Aflibercept 53 phase IIb trial 53 immuno therapeutic 53 EDRN 53 novel VDA molecule 53 PORxin TM platforms 53 autologous bone marrow 53 Fx #A 53 ZYBRESTAT fosbretabulin 53 nonhuman primate models 53 tPEMF tm 53 anti CD3 antibody 53 OHRI 53 tumorigenicity 53 adjuvant colon cancer 53 ECASS 53 diagnostic molecular imaging 53 cathepsin K inhibitor 53 vitro dissolution 53 novel oral anticoagulant 53 MERCI Retriever 53 adult chronic ITP 53 MKC# MT 53 CELVAPAN H#N# 53 Sym# 53 t2cure GmbH 53 UHCMC 53 Tesetaxel 53 Nanocort 53 targeting CD# 53 Certolizumab pegol 53 Alferon N 53 PRIMO CABG 53 Myolimus 53 lucinactant 53 Tarvacin TM 53 neuroprosthetic 53 AdhTAP 53 Dalbavancin 53 IIb clinical trial 53 Tobinick 53 LHON 53 hESC derived cardiomyocytes 53 HuMax TAC 53 opioid induced bowel dysfunction 53 R vitespen 53 masitinib 53 Initiates Phase II 53 Xerecept 53 NAVISTAR R 53 JAK3 inhibitor 53 Lytix 53 ABSORB clinical 53 metastatic uveal melanoma 53 MVA MUC1 IL2 53 dose escalation phase 53 verteporfin 53 ENMD # 53 chimeric monoclonal antibody 53 isavuconazole 53 NovaVision VRT 53 Febit 53 hematopoietic stem 53 randomized multicentre 53 ACCEDE 53 Pivotal Phase III 53 de novo kidney transplant 53 subretinal 53 microRNA profiling 53 budesonide MMX Phase III 53 either acutely decompensated 53 novel peptide 53 IDO inhibitor 53 Phase IIa proof 53 EHT AGN 53 Cannabinor 53 CLIA laboratory 53 VICTOR E1 53 Archexin 53 biliary stent 53 Enobia 53 Pertuzumab 53 TransMID TM 53 cyclophilin inhibitors 53 transplanting stem cells 52 initiated Phase Ib 52 COSIRA trial 52 APEX PD 52 Sirtex SIR Spheres microspheres 52 IPF CAPACITY 52 SMT C# 52 NADiA 52 SGLT2 inhibitors 52 developing TB4 52 bioresorbable stent 52 CyPath ® 52 cytolytic activity 52 Safinamide 52 OLYMPIA registry 52 cytokine refractory 52 sd rxRNA compounds 52 eosinophilic asthma 52 Phase 2a preventative 52 Deutsches Herzzentrum 52 Cetrorelix 52 mouse neural stem 52 Temsirolimus 52 TREAT ALS 52 patientswith 52 PresbyLens ® 52 ACTCellerate ™ 52 STEDESA 52 oral rivaroxaban 52 GED aPC 52 demonstrated antitumor activity 52 TriGrid 52 HuMax EGFr 52 lorcaserin Phase 52 Quinamed 52 EndoFLIP 52 somatostatin analog 52 relapsed MM 52 neratinib 52 multicentre study 52 depsipeptide 52 Dacogen injection 52 intradermal injections 52 GeneICE 52 Balloon sinuplasty 52 Alfimeprase 52 autologous transplant 52 CEL SCI Phase III 52 Phase lll 52 medically refractory 52 cannabinor 52 diagnostic cardiac catheterization 52 generation rotary VAD 52 Tarvacin Anti Cancer 52 Tykerb lapatinib 52 TRIST study 52 placebo controlled multicenter 52 FTIs 52 FDA Investigational Device 52 Avastin adjuvant 52 multiple myeloma MM 52 Phase Ib study 52 XCell Center 52 Tengion Neo Urinary Conduit 52 phase III SIMPADICO 52 cMET 52 Immunotherapeutic 52 deCODE AF TM 52 Eniluracil 52 Phase III confirmatory 52 Phase #/#a clinical 52 Cascade LifeSciences 52 multicenter placebo controlled 52 neovascularisation 52 Levacor 52 BEXXAR 52 Vitaxin 52 docetaxel Taxotere ® 52 functional mitral regurgitation 52 midstage clinical 52 eligen 52 ABSORB trial 52 treatment naïve genotype 52 Umbilical cord stem cells 52 vidofludimus 52 Biopartners 52 BNC# 52 DIABECELL 52 multicentre randomized 52 Protexia ® 52 allogeneic HSCT 52 Callisto initiated 52 IMC #B 52 Omacetaxine 52 CMV reactivation 52 Spectranetics laser 52 Neurologix gene 52 Urocidin 52 ALK inhibitors 52 Leber Hereditary Optic Neuropathy 52 intravesical infusion therapy 52 NGFN 52 phase IIb 52 VitiGam 52 mda 7 52 TauRx Therapeutics 52 EGFR receptor 52 bioleach 52 iii GTx 52 REVIVE Diabetes 52 recombinant tissue plasminogen 52 RSD# oral 52 immatics 52 generation purine nucleoside 52 vascular thrombosis 52 Institut Jules Bordet 52 iobenguane 52 Prodarsan ® 52 hESC derived 52 EndoTAG TM 52 transarterial 52 retinal pigment epithelial cells 52 vascular insufficiency 52 distraction osteogenesis 52 Pivotal Trial 52 Vandetanib 52 dissolving blood clots 52 inhalation toxicology 52 MitoQ 52 magnetic resonance spectroscopy MRS 52 NV1FGF 52 lorvotuzumab mertansine 52 nanomedical 52 Bendamustine 52 Advancell 52 EndoBiologics 52 Rasagiline 52 Xelox 52 LentiVector technology 52 NABTT 52 Phase 2a clinical 52 potent suppressor 52 endometrial regenerative cells 52 PF # [002] 52 assessing T DM1 52 mismatched bone marrow 52 Accuray CyberKnife 52 Phase IIa trial 52 PHX# 52 incyclinide 52 anagrelide 52 sodium stibogluconate 52 Tarceva TM 52 ZOLINZA 52 GLPG# 52 vitro toxicology 52 investigational humanized monoclonal antibody 52 AVONEX PEN 52 Optical Biopsy System 52 Dupuytren Contracture 52 pancreatic ductal 52 TMC# C# 52 gallium containing 52 Phase III placebo controlled 52 PREGNANT PROCHIEVE Extending GestatioN 52 samalizumab 52 molecular biology genomics 52 subcutaneous immunoglobulin 52 humanised monoclonal antibody 52 solanezumab 52 BETAS 52 SIR Spheres 52 multi kinase inhibitor 52 ChronVac C ® 52 Gentamicin Surgical Implant 52 Phase III ADT 52 Aryplase 52 Zybrestat 52 orally administered inhibitor 52 Fibrin MB 52 CardioPass 52 pentostatin 52 ACV1 52 Européenne Mark 52 Neuvenge 52 GRNCM1 52 telomerase inhibitor 52 HuMax Inflam 52 Excellarate TM 52 Civacir 51 Heartmate 51 pharmacology physiology 51 CytoFab 51 BAY #-# 51 DEB# 51 haematopoietic stem cell 51 Angiocept 51 MabThera rituximab 51 systemic RNAi therapeutic 51 IL-#/# 51 huC# DM4 51 BACcel 51 Tesmilifene 51 neurogenic orthostatic hypotension 51 PDE4 inhibitor 51 Prolastin A1PI 51 essential thrombocythemia ET 51 Dr. Vitetta 51 selective androgen receptor modulator 51 Diamyd ® 51 drug TGN# 51 Panzem 51 PEGylated interferon 51 UVIDEM 51 Prodarsan 51 neural regeneration 51 Ergomed 51 oxypurinol 51 JAK inhibitor 51 CRLX# 51 Cand5 51 #T# L1 51 LEUKINE 51 corneal inlay 51 rxRNA 51 MKC# 51 UPCI 51 adipose tissue derived 51 ADME PK 51 MyoCell TM 51 neuronal nicotinic receptor NNR 51 CLIA certified laboratory 51 CoreValve System 51 Remune 51 modified nucleoside 51 Multimeric 51 LHRH antagonist 51 small molecule activators 51 ALTTO 51 dilated cardiomyopathy DCM 51 enhance ApoA 51 recurrent metastatic 51 NewYork-Presbyterian/Columbia 51 Perceiva 51 QTinno TM 51 proteasome inhibitor 51 rhFVIIa 51 retinoic acid receptor 51 BLP# Liposome Vaccine 51 OvaRex MAb 51 ongoing Phase IIIb 51 Pancreate 51 inhaled AAT 51 optimal dosing regimens 51 CardioWest TAH t 51 BrainGate System 51 rt PA 51 Achieves Primary Endpoint 51 ASTEROID 51 small molecule glucokinase 51 BST CarGel R 51 kinase profiling 51 vivo molecular imaging 51 Materialise Dental 51 rBChE 51 LB# [003] 51 Phase III psoriasis 51 ImmunoGen TAP technology 51 VIBEX MTX 51 Dr. Rafii 51 Onconase 51 proteomics genomics 51 class mGluR5 inhibitor 51 validate biomarkers 51 Silodosin 51 antitumoral 51 ZFN modified 51 protein tyrosine phosphatase 1B 51 Intravenous immunoglobulin 51 canakinumab 51 MMP inhibitors 51 QNEXA ® 51 Ovonic fuel 51 PSN# [001] 51 esophageal gastric 51 TACI Ig 51 romazarit 51 radiolabeling 51 experimental autoimmune encephalomyelitis 51 Ostabolin C TM 51 ThermoDox R 51 therapeutic monoclonal antibodies 51 tubulin inhibitor 51 drug ISA# 51 plasmid encoding 51 vascular disrupting agents 51 phase IIb study 51 cells hESCs 51 Retina Implant 51 atrial fibrillation ablation 51 #beta estradiol 51 ALSYMPCA 51 Therinject 51 TBC# 51 MenSCs 51 Glioblastoma Multiforme 51 DCVax Brain 51 phenotyping 51 placebo controlled randomized 51 bile duct tumor 51 Tr DNA 51 High Impact AMPAKINE 51 renal denervation 51 midstage studies 51 inhaled formulation 51 vivo toxicology 51 Symadex 51 nitric oxide donating prostaglandin 51 bioequivalency 51 AlloMap testing 51 AVANCE Nerve Graft 51 lymphomas leukemias 51 NEUGENE R 51 prospective multicenter randomized 51 Berlin Heart EXCOR 51 Micromet BiTE 51 Personalized Immunotherapy 51 TRO# 51 JAK2 inhibitor 51 EndoTAG TM -1 51 trastuzumab DM1 51 clonogenic 51 IMiDs ® compound 51 HemoGenix 51 xenograft 51 Onalta ™ 51 Trophos 51 LEVADEX ™ 51 orally dosed 51 Clolar ® 51 ketolide antibiotic 51 ToleroMune R 51 NCI Comprehensive Cancer 51 embryonic progenitor 51 ularitide 51 translational genomics 51 XmAb 51 OAB overactive bladder 51 OncoVEX GM CSF 51 CYT# QbG# 51 CCX# B 51 molecular biology genetics 51 phase IIIb 51 regenerating tissue 51 Sorafenib Nexavar 51 CVac 51 Bevasiranib 51 Tß4 51 Pancreate ™ 51 microRNA biomarkers 51 monocytes macrophages 51 Cytometry 51 EGS# 51 OvPlex 51 PANVAC VF 51 Fc gamma receptor 51 PICM 51 anti TNFa 51 aurora kinase 51 stent coating 51 oncolytic virus therapies 51 OvaRex ® MAb 51 non nucleoside inhibitor 51 candidate deforolimus 51 Nanobody 51 multicentre 51 glucokinase activator 51 Inhaled nitric oxide 51 circulating endothelial 51 Allovectin 7 51 LungAlert TM 51 Ibis T# 51 Akonni 51 malignant ascites 51 ATIR 51 ® bortezomib 51 MCSP respectively 51 bioengineered tissue 51 Phase III registrational 51 bavituximab monotherapy trial 51 Desmoteplase 51 Duchenne muscular dystrophy DMD 51 Neurorehabilitation 51 systemic anaplastic large 51 Hospital Clínic 51 EDEMA3 51 EC Cysteamine 51 diabetic retinopathy DR 51 Alvesco R 51 NS5A inhibitor 51 gefitinib Iressa 51 amaxa 51 gastrointestinal stromal tumors GIST 51 Sanvar R 51 Pirfenidone 51 Alfacell proprietary ribonuclease 51 cisplatin resistant 51 LymphoStat B TM 51 EXPLORE Xa 51 ongoing Phase 1b 51 immunohematology 51 DermaVir Patch 51 nicotinic alpha 7 51 Removab 51 Adaptive Radiation Therapy 51 evaluating tivozanib 51 AGHD 51 rindopepimut 51 visit http:/www.clinicaltrials.gov/ 51 investigational HCV polymerase 51 mTOR inhibitors 51 Olaparib 51 novel peptides 51 OncoPet Diagnostics 51 NSCLC tumors 51 Oral NKTR 51 ALN TTR# 51 concurrent chemoradiation 51 Oxycyte TM 51 IMiDs R 51 About Rigel Rigel 51 epoetin alpha 51 selective immunoproteasome inhibitor 51 intranasal formulation 51 CIREN 51 subcutaneous methylnaltrexone 51 pharmacokinetic pharmacodynamic 51 cediranib 51 non nucleoside 51 intravenous methylnaltrexone 51 Affinitak 51 reagents kits 50 Aspergillus nidulans 50 HCV SPRINT 50 Guanilib 50 bioscavenger 50 SANVAR 50 peptide synthesis 50 antibiotic telavancin 50 molecular diagnostic assays 50 pancreatic tissue 50 osteogenic 50 Pharmos pipeline 50 Initiate Phase 50 Arzerra ofatumumab 50 WAIMR 50 oral PTH 50 carcinoma HCC 50 Initiated Phase 50 transplanting insulin